BOSTON, Oct. 8 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has posted its six-month financials on Pinksheets.com for the period ending June 30, 2008. Revenues generated through the first six-months of 2008 amounted to $204,103, compared with $151,347.53 for the comparable period in 2007. The Company saw an increase in its total cash on hand to $13,242 compared with just over $8,000 at the end of fiscal year 2007.
Solos Endoscopy, Inc. was featured in "High Growth Forecasted for the World Endoscopy Systems Market," a reported that was released on September 4, 2008 in the Reportliner.com catalog. Solos was identified extensively in the report, which analyzes the multibillion dollar worldwide market for endoscopic systems. The Company's total asset base sits just below $4,000,000 as stated in the recently released financial report.
"Solos Endoscopy has had a great first half of this year and our financials reflect that. We believe that the recent development of the Mammo View (TM) product line will greatly improve our goals of profitability and will have highly positive effect on the Company's financials within the coming New Year," stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Investor Relations for Solos Endoscopy, Inc., 1-866-THE-APPL(E)
Web site: http://www.solosendoscopy.com/
